Latest uniQure News & Updates

See the latest news and media coverage for uniQure. We track all announcements, press releases, and industry mentions in real time, all in one place.

uniQure

Gene therapy company targeting neurological and rare diseases

uniqure.com

Headquarters: Amsterdam, Netherlands
Founded year: 1998
Company type: Public company
Number of employees: 50–350

Last updated Today

Latest news about uniQure

In short: uniQure reached an agreement with the FDA to pursue accelerated approval for its Huntington’s disease gene therapy AMT-130.

Company announcements

June 17 uniQure

uniQure provides regulatory update on AMT-130 gene therapy

The update follows a meeting with the FDA regarding a path forward for the Huntington's disease treatment.

June 12 uniQure

uniQure works to develop a treatment for Huntington's disease

The company acknowledges the lack of a current treatment and thanks an article profiling Nancy Wexler.

June 6 uniQure

uniQure joins HDSA Team Hope Walk

They participated at Boston's Castle Island, raising funds for Huntington's Disease research, family services, and advocacy.

May 5 uniQure

uniQure reported Q1 2026 financial results

The company also highlighted recent progress across its business.

Media coverage

Yesterday Markets Insider

uniQure Announces $150 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing...

June 19 The Globe and Mail

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM...

June 19 Yahoo Finance

uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk

Qure is back in focus after modelled fair value estimates shifted from about US$39.05 to roughly US$52.56, a change that has fed directly into higher...

June 17 Reuters

UniQure to seek approval for Huntington's therapy after FDA U-turn, shares skyrocket

Dutch drugmaker UniQure said ‌on Wednesday the U.S. Food and Drug ⁠Administration has agreed that data from a mid-stage ...

Never miss news about uniQure

Track uniQure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

uniQure competitors & trending companies

Browse news for competitors to uniQure and other trending companies.